Evaluation of Immune Organ Dysfunction in Critical Illness

Abstract

In critically ill patients, organ dysfunction is usually assessed, monitored, and processed. Growing evidence shows that there are serious rashes caused by the disease. The immune system can be observed in most ICU patients, and persistence of an anti-inflammatory phenotype (as in sepsis-associated immunosuppression) as well as “hyper inflammatory” is associated with increased morbidity and mortality. Contrary to popular belief, changes in functional immunity are not appropriate. Creative protein, procalcitonin, or numerical analysis of the number of white blood cells (sub). Cytokines are also unsuitable for the following reasons: short half-life and pleiotropic, non-proprietary origin in immune cells; Ability to be antagonized by circulating inactivating molecules. Therefore, in addition to the quantification of leukocytes and the use of routine biomarkers, direct evaluation. The function of immune cells is obviously necessary to characterize the state of the immune system. This may include, for example, determining ex vivo release of cellular cytokines, phagocytosis. Activity and/or ability to present antigens. As a result, standardized flow cytometry Assessment of major histocompatibility complex II human leukocyte antigens (Related to D) (HLADR) was of particular interest. Monocyte HLADR (mHLADR) It modulates the interaction between innate immunity and acquired immunity and can play the following roles: “Global” Biomarkers of Trauma-Related Immunosuppression and Its Reduction manifestations may have adverse clinical outcomes (e.g., secondary infection risk, mortality). Recent data related to injuries Immunosuppression can be reversed, opening up new therapeutic possibilities in affected patients. Here we discuss its potential scientific and clinical value. Functional immunity assessment and focus on monocytes/macrophages and an overview of the current state of knowledge and potential prospects for those affected critically ill cases.